Friday, November 13, 2026
Morgan Stanley kept its Equal-Weight rating on Genmab (GMAB) and lowered its price target to $56 from $57.
Friday, October 30, 2026
Morgan Stanley kept its Equal-Weight rating on Genmab (GMAB) with a price target of $57.
Guggenheim kept its Buy rating on Genmab (GMAB) and raised its price target to $80 from $58.
Thursday, October 29, 2026
Truist Securities kept its Buy rating on Genmab (GMAB) and raised its price target to $67 from $45.
HC Wainwright & Co. kept its Buy rating on Genmab (GMAB) and raised its price target to $70 from $50.
Monday, October 26, 2026
TD Cowen kept its Buy rating on Genmab (GMAB) and raised its price target to $52 from $43.
Wednesday, October 7, 2026
Truist Securities kept its Buy rating on Genmab (GMAB) with a price target of $45.
Guggenheim kept its Buy rating on Genmab (GMAB) and raised its price target to $58 from $54.
HC Wainwright & Co. kept its Buy rating on Genmab (GMAB) and raised its price target to $50 from $40.
Monday, October 5, 2026
Guggenheim kept its Buy rating on Genmab (GMAB) and raised its price target to $54 from $42.
Monday, September 14, 2026
HC Wainwright & Co. kept its Buy rating on Genmab (GMAB).
Frequently asked questions
What is the latest news on GMAB?
Nov 13, 2026: Morgan Stanley kept its Equal-Weight rating on Genmab (GMAB) and lowered its price target to $56 from $57. (Morgan Stanley) · Oct 30, 2026: Morgan Stanley kept its Equal-Weight rating on Genmab (GMAB) with a price target of $57. (Morgan Stanley) · Oct 30, 2026: Guggenheim kept its Buy rating on Genmab (GMAB) and raised its price target to $80 from $58. (Guggenheim)
What are analysts saying about GMAB?
Nov 13, 2026: Morgan Stanley kept its Equal-Weight rating on Genmab (GMAB) and lowered its price target to $56 from $57. · Oct 30, 2026: Morgan Stanley kept its Equal-Weight rating on Genmab (GMAB) with a price target of $57. · Oct 30, 2026: Guggenheim kept its Buy rating on Genmab (GMAB) and raised its price target to $80 from $58.
Get GMAB news as it happens
Every headline, SEC filing and analyst action for GMAB on your live chart, with important news marked and alerts when it matters.
Try SEPT Free